Company / Operating Cash Flow
Caribou Biosciences, Inc. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$111.0M
FY2025
5-year range
-$111.0M / -$32.0M
FY2021-FY2025
Trend
-19.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 4 consecutive years, from -$32M in FY2021 to -$111M in FY2025.
Based on SEC 10-K filings.
-$111M in FY2025.
Declined from -$91M to -$111M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Caribou Biosciences, Inc.'s operating cash flow has declined for 4 consecutive years.
- In FY2025, operating cash flow decreased 19.0% year-over-year.
- Peak operating cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$111.0M | -19.0% |
| FY2024 | -$93.3M | -2.6% |
| FY2023 | -$91.0M | -179.7% |
| FY2022 | -$32.5M | -1.6% |
| FY2021 | -$32.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026